Dr. Richard N. Spivey Ph.D. is Independent Director of the company. Dr. Spivey has over 30 years of experience in research and development at leading global pharmaceutical companies. Dr. Spivey currently serves as a scientific advisor to the pharmaceutical industry. From 2010 to 2015, Dr. Spivey served as senior vice president of global regulatory affairs at Allergan. From 2002 to 2010, Dr. Spivey worked with Meda AB, a pharmaceutical company, after its acquisition of MedPointe Pharmaceuticals, serving as chief scientific officer and head of research and development for both. Earlier in his career, Dr. Spivey worked for pharmaceutical companies Pharmacia Corporation (now part of Pfizer), Schering-Plough Corporation (now part of Merck & Co.), Parke-Davis/Warner-Lambert (now part of Pfizer), and Boots Pharmaceuticals, Inc. Dr. Spivey previously served on the board of directors of Inotek Pharmaceuticals Corporation (now Rocket Pharmaceuticals, Inc.). Dr. Spivey received a Ph.D. in Pharmacy Administration from the University of Minnesota and a Pharm.D. from the University of Southern California. Dr. Spivey has been chosen to serve on our Board due to his extensive and distinguished experience in drug development and regulatory affairs.
As the Independent Director of Adverum Biotechnologies Inc, the total compensation of Richard Spivey at Adverum Biotechnologies Inc is $483,851. There are 9 executives at Adverum Biotechnologies Inc getting paid more, with Leone Patterson having the highest compensation of $2,830,320.
Richard Spivey is 69, he's been the Independent Director of Adverum Biotechnologies Inc since 2017. There are no older and 18 younger executives at Adverum Biotechnologies Inc.
Richard's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK, CA, 94025.
Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard e Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include: